Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0190-9622(86)80357-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Serum IL-23 levels reflect a myeloid inflammatory signature and predict the response to apremilast in patients with psoriatic arthritis.
Front Immunol
December 2024
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
Background: The phosphodiesterase 4 (PDE4) inhibitor apremilast downregulates the production of IL-23 and other pro-inflammatory cytokines involved in the pathogenesis of psoriatic arthritis (PsA).
Aim: To investigate the effects of apremilast on the production of cytokines by peripheral blood monocyte-derived macrophages, innate-like lymphocyte cells (ILCs), mucosal-associated invariant T (MAIT) cells, γδ T cells, natural killer (NK) cells, and NKT-like cells from patients with PsA manifesting different clinical responses to the treatment.
Methods: Peripheral blood samples were obtained from patients with PsA at baseline and after 1 and 4 months of apremilast therapy (n = 23) and 20 controls with osteoarthritis.
Systematic review of biologic use for psoriasis in HIV-positive individuals from 2018 to 2024.
Arch Dermatol Res
November 2024
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
Article Synopsis
- - Psoriasis is a long-term inflammatory skin condition linked to T-lymphocyte activation, and treating it in individuals with HIV is challenging due to immune system complications.
- - This study reviewed 19 articles involving 24 cases of psoriasis in people with HIV, analyzing various therapies like apremilast and ustekinumab, which showed effectiveness in reducing skin symptoms and even some cases of psoriatic arthritis.
- - Although adverse events were rare and manageable, more comprehensive research is needed to clearly understand the safety and efficacy of these treatments for HIV-positive patients.
Pomalidomide in patients with multiple myeloma: potential impact on the reconstitution of a functional T-cell immunity.
Immunol Res
December 2024
Department of Medicine, Surgery and Pharmacy, University of Sassari, Viale San Pietro 12, 07100, Sassari, Italy.
Background: Pomalidomide, a third-generation oral immunomodulatory drug, exhibits efficacy in patients with relapsed multiple myeloma or those refractory to bortezomib and lenalidomide (RRMM).
Methods: In this clinical context, we employed flow cytometry and CDR3 spectratyping to monitor the dynamics of the T-cell repertoire during Pomalidomide treatment, aiming to investigate its potential to reverse the immunological abnormalities characteristic of RRMM.
Results: By flow cytometry at baseline we found a significant decrease in CD4 + frequency in MM patients, while CD8 + frequency were significantly higher in patients when compared to controls.
The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial.
Nat Commun
August 2024
Adult Hematologic Malignancies & Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Functional blockade of the transforming growth factor-beta (TGFβ) signalling pathway improves the efficacy of cytotoxic and immunotherapies. Here, we conducted a phase 1b study (ClinicalTrials.gov.
View Article and Find Full Text PDFClinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial.
Nat Cancer
October 2024
Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Persons with myeloma were randomized to receive an anti-TIGIT (T cell immunoreceptor) or anti-LAG3 (lymphocyte activation gene) antibody followed by combination with pomalidomide and dexamethasone ( NCT04150965 ). Primary and secondary endpoints were safety and efficacy, respectively. Therapy was well tolerated without dose-limiting toxicity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!